ESMO 2019 | BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, discusses the BROCADE3 trial (NCT02163694). This trial is investigating the efficacy and tolerability of veliparib vs. a placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Get great new content delivered to your inboxSign up